

Cancer Support Community and Subsidiary

Consolidated Financial Statements and Supplementary Information

December 31, 2019 and 2018
with Independent Auditors' Report

TABLE OF CONTENTS

| | |
|--|------|
| Independent Auditors' Report | 1-2 |
| Consolidated Financial Statements | |
| Consolidated Statements of Financial Position | 3 |
| Consolidated Statements of Activities..... | 4-5 |
| Consolidated Statements of Functional Expenses | 6-7 |
| Consolidated Statements of Cash Flows..... | 8 |
| Notes to the Consolidated Financial Statements..... | 9-18 |
| Supplementary Information | |
| Consolidating Statement of Financial Position | 19 |
| Consolidating Statement of Activities | 20 |

INDEPENDENT AUDITORS' REPORT

Board of Directors
Cancer Support Community and Subsidiary:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Cancer Support Community (a not-for-profit organization) and Subsidiary which comprise the consolidated statements of financial position as of December 31, 2019 and 2018, and the related consolidated statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Cancer Support Community and Subsidiary as of December 31, 2019 and 2018, and the changes in their consolidated net assets and their consolidated cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The consolidating statement of financial position and consolidating statement of activities on pages 19 - 20 are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Clark, Schaefer, Hackett & Co.

Cincinnati, Ohio
June 17, 2020

Cancer Support Community and Subsidiary
Consolidated Statements of Financial Position
December 31, 2019 and 2018

Assets:

| | 2019 | 2018 |
|-----------------------------|---------------|------------|
| Cash and cash equivalents | \$ 2,676,766 | 1,486,517 |
| Restricted cash | 4,360,627 | 5,046,879 |
| Accounts receivable, net | 1,727,053 | 1,487,847 |
| Prepaid expenses | 190,272 | 100,763 |
| Investments | 2,414,766 | 2,015,533 |
| Property and equipment, net | 954,522 | 1,062,355 |
| Deposits | 106,183 | 106,183 |
| Total assets | \$ 12,430,189 | 11,306,077 |

Liabilities and Net Assets

Liabilities:

| | | |
|-------------------|------------|---------|
| Accounts payable | \$ 364,117 | 381,937 |
| Accrued expenses | 115,856 | 102,050 |
| Deferred revenue | 201,963 | 68,584 |
| Other liabilities | 392,044 | 375,215 |
| Total liabilities | 1,073,980 | 927,786 |

Net assets:

| | | |
|----------------------------------|---------------|------------|
| Without donor restrictions: | | |
| Controlling interest | 3,798,092 | 1,918,951 |
| Noncontrolling interest in PPS | (36,781) | (21,762) |
| Total without donor restrictions | 3,761,311 | 1,897,189 |
| With donor restrictions | 7,594,898 | 8,481,102 |
| Total net assets | 11,356,209 | 10,378,291 |
| Total liabilities and net assets | \$ 12,430,189 | 11,306,077 |

See accompanying notes to the consolidated financial statements.

Cancer Support Community and Subsidiary
Consolidated Statement of Activities
Year Ended December 31, 2019

| | <u>Without Donor</u> <u>Restrictions</u> | <u>With Donor</u> <u>Restrictions</u> | <u>Total</u> |
|--|---|--|-------------------|
| Revenues and other support: | | | |
| Contributions: | | | |
| Development income | \$ 1,013,080 | - | 1,013,080 |
| Program | 158,420 | 1,212,793 | 1,371,213 |
| Research and training | 1,047,274 | 810,564 | 1,857,838 |
| Events and special initiatives | 386,273 | 896,660 | 1,282,933 |
| Digital services and web | 386,688 | 173,680 | 560,368 |
| Education/Outreach | 1,011 | 2,215,000 | 2,216,011 |
| Policy/Advocacy | 1,171,500 | 1,065,740 | 2,237,240 |
| Special purpose funds | 75,019 | - | 75,019 |
| In-kind revenue | 9,443 | - | 9,443 |
| Affiliate activities | 520,310 | - | 520,310 |
| PPS sales, net of direct costs of \$52,477 | 220,531 | - | 220,531 |
| Miscellaneous income | 30,808 | - | 30,808 |
| Net investment return | 438,809 | - | 438,809 |
| Net assets released from restrictions | <u>7,260,641</u> | <u>(7,260,641)</u> | <u>-</u> |
| Total revenues and support | <u>12,719,807</u> | <u>(886,204)</u> | <u>11,833,603</u> |
| Expenses: | | | |
| Program services | 8,732,962 | - | 8,732,962 |
| Management and general | 729,633 | - | 729,633 |
| Fundraising | 838,796 | - | 838,796 |
| Operating expenses: PPS | <u>554,294</u> | <u>-</u> | <u>554,294</u> |
| Total expenses | <u>10,855,685</u> | <u>-</u> | <u>10,855,685</u> |
| Change in net assets | 1,864,122 | (886,204) | 977,918 |
| Net assets at beginning of year | <u>1,897,189</u> | <u>8,481,102</u> | <u>10,378,291</u> |
| Net assets at end of year | \$ <u>3,761,311</u> | <u>7,594,898</u> | <u>11,356,209</u> |

See accompanying notes to the consolidated financial statements.

Cancer Support Community and Subsidiary
Consolidated Statement of Activities
Year Ended December 31, 2018

| | Without Donor Restrictions | With Donor Restrictions | Total |
|--|-------------------------------|----------------------------|-------------------|
| Revenues and other support: | | | |
| Contributions: | | | |
| Development income | \$ 799,196 | - | 799,196 |
| Program | 24,708 | 1,061,948 | 1,086,656 |
| Research and training | 81,630 | 1,089,414 | 1,171,044 |
| Events and special initiatives | 1,078,370 | - | 1,078,370 |
| Digital services and web | 236,000 | 455,000 | 691,000 |
| Education/Outreach | 147,592 | 1,904,400 | 2,051,992 |
| Policy/Advocacy | 323,162 | 1,403,088 | 1,726,250 |
| Special purpose funds | 300,920 | - | 300,920 |
| In-kind revenue | 163,279 | - | 163,279 |
| Affiliate activities | 576,234 | - | 576,234 |
| PPS sales, net of direct costs of \$98,456 | 328,609 | - | 328,609 |
| Miscellaneous income | 12,284 | - | 12,284 |
| Net investment return | (95,804) | - | (95,804) |
| Acquisition of MyLifeLine | 511,271 | - | 511,271 |
| Net assets released from restrictions | <u>6,395,688</u> | <u>(6,395,688)</u> | <u>-</u> |
| Total revenues and support | <u>10,883,139</u> | <u>(481,838)</u> | <u>10,401,301</u> |
| | | | |
| Expenses: | | | |
| Program services | 8,343,883 | - | 8,343,883 |
| Management and general | 637,585 | - | 637,585 |
| Fundraising | 916,639 | - | 916,639 |
| Operating expenses: PPS | <u>444,920</u> | <u>-</u> | <u>444,920</u> |
| Total expenses | <u>10,343,027</u> | <u>-</u> | <u>10,343,027</u> |
| | | | |
| Change in net assets | 540,112 | (481,838) | 58,274 |
| | | | |
| Net assets at beginning of year | <u>1,357,077</u> | <u>8,962,940</u> | <u>10,320,017</u> |
| | | | |
| Net assets at end of year | \$ <u>1,897,189</u> | <u>8,481,102</u> | <u>10,378,291</u> |

See accompanying notes to the consolidated financial statements.

Cancer Support Community and Subsidiary
Consolidated Statement of Functional Expenses
Year Ended December 31, 2019

| | Program Services | Supporting Services | | Operating Expenses: PPS | Total |
|--|---------------------|---------------------------|----------------|----------------------------|-------------------|
| | | Management and General | Fundraising | | |
| Salaries and related expenses: | | | | | |
| Salaries | \$ 3,739,038 | 294,413 | 201,740 | 360,011 | 4,595,202 |
| Payroll taxes and employee benefits | <u>713,124</u> | <u>56,152</u> | <u>38,476</u> | <u>34,583</u> | <u>842,335</u> |
| Total salaries and related expenses | <u>4,452,162</u> | <u>350,565</u> | <u>240,216</u> | <u>394,594</u> | <u>5,437,537</u> |
| Other expenses: | | | | | |
| Office expenses | 270,277 | 10,048 | 10,869 | 1,411 | 292,605 |
| Grant expenses | 797,009 | - | - | - | 797,009 |
| Conferences and meetings | 45,665 | 48,371 | 3,316 | 8,070 | 105,422 |
| Consulting | 1,223,593 | 14,882 | 65,070 | - | 1,303,545 |
| Research and development | 110,620 | - | - | - | 110,620 |
| Dues and subscriptions | 45,212 | 16,794 | 4,492 | - | 66,498 |
| Equipment rental | 16,185 | 602 | 650 | - | 17,437 |
| Liability insurance | 27,434 | 1,020 | 1,103 | 28,982 | 58,539 |
| Travel | 314,634 | 31,816 | 62,023 | 14,464 | 422,937 |
| Marketing and recruiting | 66,647 | 15,596 | 16,661 | - | 98,904 |
| Postage and delivery | 22,173 | 7,281 | 3,640 | 438 | 33,532 |
| Printing and publications | 45,467 | 16,845 | - | 7,236 | 69,548 |
| Affiliate | 112,141 | - | - | - | 112,141 |
| Occupancy | 624,793 | 23,228 | 25,125 | 3,500 | 676,646 |
| Special events | - | - | 357,343 | - | 357,343 |
| Professional fees | - | - | - | 56,343 | 56,343 |
| Miscellaneous | 29,379 | 32,798 | 26,791 | 17,968 | 106,936 |
| Bad debt expense | - | 101,311 | - | 13,700 | 115,011 |
| In-kind expenses | 9,443 | - | - | - | 9,443 |
| CSC on-line | <u>317,099</u> | <u>36,034</u> | <u>7,207</u> | <u>-</u> | <u>360,340</u> |
| Total other expenses | <u>4,077,771</u> | <u>356,626</u> | <u>584,290</u> | <u>152,112</u> | <u>5,170,799</u> |
| Total expenses before depreciation | 8,529,933 | 707,191 | 824,506 | 546,706 | 10,608,336 |
| Depreciation | <u>203,029</u> | <u>22,442</u> | <u>14,290</u> | <u>7,588</u> | <u>247,349</u> |
| Total expenses | \$ <u>8,732,962</u> | <u>729,633</u> | <u>838,796</u> | <u>554,294</u> | <u>10,855,685</u> |

See accompanying notes to the consolidated financial statements.

Cancer Support Community and Subsidiary
Consolidated Statement of Functional Expenses
Year Ended December 31, 2018

| | Program Services | Supporting Services | | Operating Expenses: PPS | Total |
|--|----------------------------|---------------------------|-----------------------|----------------------------|--------------------------|
| | | Management and General | Fundraising | | |
| Salaries and related expenses: | | | | | |
| Salaries | \$ 3,247,270 | 271,697 | 177,334 | 350,737 | 4,047,038 |
| Payroll taxes and employee benefits | <u>587,198</u> | <u>49,131</u> | <u>32,067</u> | <u>33,086</u> | <u>701,482</u> |
| Total salaries and related expenses | <u>3,834,468</u> | <u>320,828</u> | <u>209,401</u> | <u>383,823</u> | <u>4,748,520</u> |
| Other expenses: | | | | | |
| Office expenses | 210,052 | 11,449 | 12,150 | 564 | 234,215 |
| Grant expenses | 710,787 | - | - | - | 710,787 |
| Conferences and meetings | 39,702 | 37,619 | 3,395 | 3,407 | 84,123 |
| Consulting | 1,680,929 | 23,064 | 102,648 | - | 1,806,641 |
| Research and development | 48,749 | - | - | - | 48,749 |
| Dues and subscriptions | 42,440 | 7,477 | 22,898 | - | 72,815 |
| Equipment rental | 17,498 | 954 | 1,012 | - | 19,464 |
| Liability insurance | 22,596 | 1,232 | 1,307 | 18,894 | 44,029 |
| Travel | 262,729 | 26,697 | 84,182 | 11,664 | 385,272 |
| Marketing and recruiting | 37,789 | 20,962 | 9,447 | 29 | 68,227 |
| Postage and delivery | 24,792 | 8,141 | 4,071 | 610 | 37,614 |
| Printing and publications | 159,569 | 36,862 | 6,473 | 20 | 202,924 |
| Affiliate | 177,875 | - | - | - | 177,875 |
| Occupancy | 571,774 | 31,165 | 33,072 | 525 | 636,536 |
| Special events | - | - | 394,859 | - | 394,859 |
| Professional fees | - | - | - | 15,723 | 15,723 |
| Miscellaneous | 15,390 | - | 14,813 | 9,661 | 39,864 |
| Bad debt expense | - | 75,000 | - | - | 75,000 |
| In-kind expenses | 163,279 | - | - | - | 163,279 |
| CSC on-line | <u>122,875</u> | <u>13,963</u> | <u>2,793</u> | <u>-</u> | <u>139,631</u> |
| Total other expenses | <u>4,308,825</u> | <u>294,585</u> | <u>693,120</u> | <u>61,097</u> | <u>5,357,627</u> |
| Total expenses before | 8,143,293 | 615,413 | 902,521 | 444,920 | 10,106,147 |
| Depreciation | <u>200,590</u> | <u>22,172</u> | <u>14,118</u> | <u>-</u> | <u>236,880</u> |
| Total expenses | \$ <u><u>8,343,883</u></u> | <u><u>637,585</u></u> | <u><u>916,639</u></u> | <u><u>444,920</u></u> | <u><u>10,343,027</u></u> |

See accompanying notes to the consolidated financial statements.

Cancer Support Community and Subsidiary
Consolidated Statements of Cash Flows
Years Ended December 31, 2019 and 2018

| | 2019 | 2018 |
|---|--------------|-----------|
| Cash flows from operating activities: | | |
| Change in net assets | \$ 977,918 | 58,274 |
| Adjustments to reconcile change in net assets to net cash provided by operating activities: | | |
| Bad debt expense | 115,011 | 75,000 |
| Unrealized and realized (gain) loss on investments | (352,778) | 151,902 |
| Depreciation | 247,349 | 236,880 |
| Acquisition of MyLifeLine | - | (511,271) |
| Effects of change in operating assets and liabilities: | | |
| Accounts receivable | (354,217) | 640,866 |
| Prepaid expenses | (89,509) | 24,153 |
| Deposits | - | 10,489 |
| Accounts payable | (17,820) | 136,720 |
| Accrued expenses | 13,806 | (77,941) |
| Deferred revenue | 133,379 | (70,987) |
| Other liabilities | 16,829 | 26,244 |
| Net cash provided by operating activities | 689,968 | 700,329 |
| Cash flows from investing activities: | | |
| Purchase of investments | (46,455) | (50,896) |
| Cash from MyLifeLine acquisition | - | 408,174 |
| Acquisition of property and equipment | (139,516) | - |
| Net cash provided (used) by investing activities | (185,971) | 357,278 |
| Change in cash, cash equivalents and restricted cash | 503,997 | 1,057,607 |
| Cash, cash equivalents and restricted cash - beginning of year | 6,533,396 | 5,475,789 |
| Cash, cash equivalents and restricted cash - end of year | \$ 7,037,393 | 6,533,396 |
| Supplemental disclosures: | | |
| Acquisition of MyLifeLine assets and liabilities: | | |
| Accounts receivable | \$ - | 75,000 |
| Prepaid expenses | - | 37,424 |
| Accounts payable | - | (1,175) |
| Accrued expenses | - | (3,152) |
| Deferred revenue | - | (5,000) |
| | \$ - | 103,097 |

See accompanying notes to the consolidated financial statements.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

The following accounting principles and practices of Cancer Support Community and Subsidiary (collectively known as "CSC") are set forth to facilitate the understanding of data presented in the consolidated financial statements.

Nature of operations

The mission of the Cancer Support Community is to ensure that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. In 2009, The Wellness Community and Gilda's Club joined forces to become the Cancer Support Community.

As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC) is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. CSC achieves its mission through three areas: direct service delivery, research, and advocacy. The organization includes an international network of affiliates that offer the highest quality social and emotional support for people impacted by cancer, as well as a community of support available online and over the phone. The Research and Training Institute conducts cutting-edge psychosocial, behavioral and survivorship research. CSC furthers its focus on patient advocacy through the Cancer Policy Institute, informing public policy in Washington D.C. and across the nation. The Cancer Support Community is advancing the innovations that are becoming the standard in complete cancer care.

Individual gifts, corporate and foundation contributions, and educational grants are the major sources of support for CSC.

Patient Planning Services, Inc. ("PPS") is a majority-owned Texas C-Corp established in 2013 to license a distress screening tool for cancer patients. It was initially funded by a \$100,000 investment by CSC which received that money as a donation. CSC licenses the distress tool to PPS which in turn licenses to hospitals.

During 2018, CSC acquired the operations of MyLifeLine, Inc. ("MLL"), a not-for-profit organization with a mission to easily connect cancer patients, friends and families through a digital platform. Upon the effective date of the acquisition, MLL was merged into CSC, the surviving corporation.

Basis of consolidation

The consolidated financial statements include the accounts of CSC and PPS. All material inter-entity transactions have been eliminated.

CSC applies the accounting treatment of the majority owner and its relationship with the deficits in the noncontrolling interest. The amount of intercompany profit or loss to be eliminated is not affected by the existence of a noncontrolling interest. The complete elimination of the intercompany profit or loss is consistent with the underlying assumption that consolidated statements represent the financial position and operating results of a single business enterprise. The elimination of the intercompany profit or loss may be allocated proportionately between the majority and noncontrolling interests.

Financial Accounting Standards Board (FASB) requires that ownership interests in subsidiaries held by parties other than the parent to be clearly identified. In addition, it requires that the amount of

consolidated excess of revenue over expense attributable to the parent and to the noncontrolling interest be clearly identified and presented on the face of the consolidated statements of activities. FASB also requires the recognition of a noncontrolling interest in the net assets without donor restrictions class in the consolidated statements of financial position separate from the net assets without donor restrictions. The excess of revenue over expenses attributable to the noncontrolling interest is included in the consolidated statements of activities. The incremental effects of applying the provisions on the individual lines of the consolidated financial statements as of and for the year ended December 31, 2019 and 2018, are presented in the consolidated financial statements and included in Note 9 to the consolidated financial statements.

Adoption of new accounting standards

During 2019, CSC adopted the following FASB Accounting Standards Updates (ASU):

ASU 2018-08, *Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made*. The standard will assist entities in determining whether transactions should be recorded as a contribution (nonreciprocal) transaction or as an exchange (reciprocal) transaction. The standard also provides expanded guidance on determining whether or not a contribution is conditional. CSC has applied this standard on a modified prospective basis for the period beginning January 1, 2019. There was no material impact to the consolidated financial statements presented upon adoption of this standard.

ASU 2016-18, *Statement of Cash Flows (Topic 230) – Restricted Cash*. The standard addresses the disclosures required for restricted cash and requires restricted cash to be included with cash and cash equivalents in the reconciliation of the total cash balance on the consolidated statements of cash flows. CSC has implemented this guidance and applied retrospectively to all periods presented.

Use of estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Financial statement presentation

CSC reports information regarding its consolidated financial position and activities according to the following net asset classifications:

- Net assets without donor restrictions: Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of CSC. These net assets may be used at the discretion of CSC's management and the Board of Directors.
- Net assets with donor restrictions: Net assets subject to stipulations imposed by donors. Some donor restrictions are temporary in nature; those restrictions that are likely to be met by actions of CSC or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

Contributions

Contributions of cash and other assets without donor stipulations concerning the use of such assets are reported as revenues of the net assets without donor restrictions class. Contributions of cash or other assets

to be used in accordance with donor stipulations are reported as revenues of the net assets with donor restrictions class.

The expiration of a donor-imposed restriction on a contribution is recognized in the period in which the restriction expires and at that time the related resources are reclassified to net assets without donor restrictions. A restriction expires when the stipulated time period has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both. Donor-restricted contributions whose restrictions are met in the same reporting period are reported as net assets with donor restrictions and then released from restriction and reclassified to net assets without donor restriction.

Income taxes

For Federal tax purposes, CSC is an exempt organization under Section 501(c)(3) of the Internal Revenue Code. In addition, CSC has been determined by the Internal Revenue Service not to be a private foundation within the meaning of Section 509(a) of the Internal Revenue Code. CSC does not believe it had any income that would be considered unrelated business income.

Cash, cash equivalents and restricted cash

For purposes of the consolidated statements of cash flows, CSC considers all highly liquid investments with initial maturities of three months or less to be cash equivalents. CSC maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. CSC has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit risk on cash. CSC has collected cash from donors with restrictions for specified CSC programs that is reported as restricted cash on the consolidated statements of financial position.

Cash, cash equivalents and restricted cash reported within the consolidated statements of financial position that aggregate to the total reported on the consolidated statements of cash flows are as follows at December 31:

| | <u>2019</u> | <u>2018</u> |
|---------------------------|---------------------|------------------|
| Cash and cash equivalents | \$ 2,676,766 | 1,486,517 |
| Restricted cash | <u>4,360,627</u> | <u>5,046,879</u> |
| | <u>\$ 7,037,393</u> | <u>6,533,396</u> |

Investments

Investments are carried at the fair value of the securities. Net investment return consists of interest, dividends, capital gain distributions, unrealized gain (loss) and investment fees.

Allowance for doubtful accounts

CSC carries its accounts receivable at the amount earned less an allowance for doubtful accounts. On a periodic basis, CSC evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. As of December 31, 2018, an allowance for doubtful accounts of \$75,000 was recognized. Management deemed no allowance necessary at December 31, 2019.

Property and equipment

Property and equipment is stated at cost or fair value, if donated. CSC capitalizes assets with a cost or fair value of at least \$500. Depreciation is computed using the straight-line method over three, five, seven and twenty-year lives.

In-kind contributions

CSC records in-kind services as revenue in the consolidated financial statements at their estimated fair value. In-kind services are not recorded if no objective basis is available to measure the value received by CSC. During 2019 and 2018, CSC received in-kind services of \$9,443 and \$163,279, respectively.

Functional allocation of expenses

The costs of providing program and other activities have been summarized on a functional basis in the consolidated statements of activities. Accordingly, certain costs have been allocated among program services and supporting services benefited. All fundraising costs are charged to fundraising; there are no joint costs. Such allocations are determined by management on an equitable basis. The expenses that are allocated include the following:

| <u>Expense</u> | <u>Method of Allocation</u> |
|---|-----------------------------|
| Salaries, payroll taxes and employee benefits | time and effort |
| Office expenses, conferences and meetings, consulting, dues and subscriptions, equipment rental, liability insurance, travel, marketing and recruiting, postage and delivery, printing and publications, occupancy, miscellaneous and CSC on-line | full-time equivalents |

Reclassifications

Certain items in the 2018 report have been reclassified to conform to current year classifications. Such reclassifications have no effect on previously reported change in net assets.

Subsequent events

CSC evaluates events and transactions occurring subsequent to the date of the consolidated financial statements for matters requiring recognition or disclosure in the consolidated financial statements. The accompanying consolidated financial statements consider events through June 17, 2020, the date on which the consolidated financial statements were available to be issued.

2. INVESTMENTS:

Generally accepted accounting principles define fair value, establish a framework for measuring fair value, and establish a fair value hierarchy that prioritizes the inputs to valuation techniques. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value.

The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities CSC has the ability to access.
- Level 2 inputs are inputs (other than quoted prices included within Level 1) that are observable for the asset or liability, either directly or indirectly.
- Level 3 are unobservable inputs for the asset or liability and rely on management's own assumptions about the assumptions that market participants would use in pricing the asset or liability.

The following tables present CSC's fair value hierarchy for those assets measured at fair value on a recurring basis as of December 31, 2019 and 2018.

Fair Value Measurements at Reporting Date Using

| | <u>Total</u> | <u>Level 1</u> | <u>Level 2</u> | <u>Level 3</u> |
|--------------------------|---------------------|------------------|----------------|----------------|
| <u>December 31, 2019</u> | | | | |
| Money market funds | \$ 172,397 | 172,397 | - | - |
| Fixed income funds | 683,481 | 683,481 | - | - |
| Equity funds | <u>1,558,888</u> | <u>1,558,888</u> | - | - |
| Total | <u>\$ 2,414,766</u> | <u>2,414,766</u> | - | - |

Fair Value Measurements at Reporting Date Using

| | <u>Total</u> | <u>Level 1</u> | <u>Level 2</u> | <u>Level 3</u> |
|--------------------------|---------------------|------------------|----------------|----------------|
| <u>December 31, 2018</u> | | | | |
| Money market funds | \$ 125,942 | 125,942 | - | - |
| Fixed income funds | 645,868 | 645,868 | - | - |
| Equity funds | <u>1,243,723</u> | <u>1,243,723</u> | - | - |
| Total | <u>\$ 2,015,533</u> | <u>2,015,533</u> | - | - |

3. PROPERTY AND EQUIPMENT:

Property and equipment consisted of the following at December 31:

| | <u>2019</u> | <u>2018</u> |
|--------------------------------|--------------------|--------------------|
| Leasehold improvements | \$ 1,223,546 | 1,114,835 |
| Office furniture and equipment | 330,761 | 332,831 |
| Software | <u>668,128</u> | <u>728,212</u> |
| | 2,222,435 | 2,175,878 |
| Less accumulated depreciation | <u>(1,267,913)</u> | <u>(1,113,523)</u> |
| | <u>\$ 954,522</u> | <u>1,062,355</u> |

4. NET ASSETS WITH DONOR RESTRICTIONS:

Net assets with donor restrictions are restricted for the following purposes at December 31:

| | <u>2019</u> | <u>2018</u> |
|--|---------------------|------------------|
| Subject to expenditure for a specific purpose: | | |
| Policy/Advocacy | \$ 1,242,423 | 1,479,986 |
| HIV Distress | - | 216,782 |
| Cost Eff/ION Project | - | 80,000 |
| Digital Website and Tech Infrastructure | 189,761 | 305,000 |
| My IO Manager | 565,800 | 1,114,887 |
| National Call Center | 541,891 | 640,716 |
| Frankly Speaking About Cancer Programs | 2,654,547 | 2,272,649 |
| Education and outreach | 325,622 | - |
| Healing Spaces Hospital Partnership Program | - | 326,783 |
| Meals at Home | 63,603 | 43,680 |
| Cancer Experience Registry | 1,403,201 | 1,345,774 |
| Open to Options Programs | 285,000 | 204,161 |
| Navajo nations | 63,050 | - |
| Other programs | <u>250,000</u> | <u>440,684</u> |
| | <u>7,584,898</u> | <u>8,471,102</u> |
| Restricted by donor in perpetuity | <u>10,000</u> | <u>10,000</u> |
| Total net assets with donor restrictions | \$ <u>7,594,898</u> | <u>8,481,102</u> |

During the years ended December 31, 2019 and 2018, net assets released from restrictions were \$7,260,641 and \$6,395,688, respectively.

5. RELATED PARTIES:

CSC received fees from local affiliates in the amount of \$520,310 and \$576,234 during the years ended December 31, 2019 and 2018, respectively. Expenditures related to these local affiliates totaled \$112,142 and \$177,875 during the years ended December 31, 2019 and 2018, respectively. At December 31, 2019 and 2018, CSC had amounts due to affiliates (included in accounts payable) of \$22,125 and \$2,550, respectively, and amounts due from affiliates (included in accounts receivable) of \$67,962 and \$63,814, respectively.

6. LEASES:

CSC leases office spaces under non-cancelable operating leases that expire in various years through November 2033. CSC also leases office equipment under non-cancelable operating leases that expire in various years through 2024.

Future minimum lease payments under all the lease agreements at December 31, 2019 are as follows:

| | |
|------------|---------------------|
| 2020 | \$ 603,042 |
| 2021 | 614,817 |
| 2022 | 591,653 |
| 2023 | 479,492 |
| 2024 | 487,818 |
| Thereafter | <u>2,056,583</u> |
| | <u>\$ 4,833,405</u> |

Total rent expense was \$563,875 and \$528,249 for the years ended December 31, 2019 and 2018, respectively.

7. PENSION PLAN:

CSC has a match through their 403(b) retirement plan providing annual benefits to employees equal to 3% of their gross salaries. Employees are eligible the first day of hire to enter the plan, are eligible for the match after 1 year of service and are vested over 3 years in the employer's contribution. Employer contributions of \$92,947 and \$88,217 were made for the years ended December 31, 2019 and 2018, respectively.

8. MYLIFELINE ACQUISITION:

Effective January 2, 2018, CSC acquired MyLifeLine, Inc. a Colorado not-for-profit. MLL maintained its operations, however, the entity is now reported as a component of CSC. All net assets assumed were without donor restrictions. The following assets and liabilities were assumed as part of the acquisition:

| | |
|---------------------------|-------------------|
| Cash and cash equivalents | \$ 408,174 |
| Accounts receivable | 75,000 |
| Other current assets | 37,424 |
| Accounts payable | (1,175) |
| Accrued expenses | (3,152) |
| Deferred revenue | <u>(5,000)</u> |
| | <u>\$ 511,271</u> |

9. CONSOLIDATION:

In March 2014, CSC sold 4,761 shares of preferred stock of PPS to an unrelated investor for \$100,000. This represents a noncontrolling ownership interest in PPS of 4.5%.

The change in consolidated net assets without donor restrictions attributed to controlling and noncontrolling interests are as follows:

| | <u>Total</u> | <u>Controlling Interest</u> | <u>Noncontrolling Interest</u> |
|---|---------------------|---------------------------------|------------------------------------|
| Balance at December 31, 2017 | \$ 1,357,077 | 1,373,605 | (16,528) |
| Change in net assets without donor restrictions of CSC | 656,423 | 656,423 | - |
| Change in net assets without donor restrictions of PPS | <u>(116,311)</u> | <u>(111,077)</u> | <u>(5,234)</u> |
| Balance at December 31, 2018 | \$ <u>1,897,189</u> | <u>1,918,951</u> | <u>(21,762)</u> |
| Change in net assets without donor restrictions of CSC | 2,197,885 | 2,197,885 | - |
| Change in net assets without donor restrictions of PPS | <u>(333,763)</u> | <u>(318,744)</u> | <u>(15,019)</u> |
| Balance at December 31, 2019 | \$ <u>3,761,311</u> | <u>3,798,092</u> | <u>(36,781)</u> |

10. CONTINGENCIES:

CSC is subject to claims and lawsuits which arise primarily in the ordinary course of its activities. It is the opinion of management that the disposition or ultimate resolution of such claims and lawsuits will not have a material adverse effect on the consolidated financial position, change in net assets and cash flows of CSC.

11. LIQUIDITY DISCLOSURES:

CSC is substantially supported by contributions from donors. Because a donor's restriction requires resources to be used in a particular manner or in a future period, CSC must maintain sufficient resources to meet those responsibilities to its donors. Thus, financial assets may not be available for general expenditure within one year. As part of CSC's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due.

The following table presents the financial assets available to meet cash needs for general expenditures within one year at December 31:

| | <u>2019</u> | <u>2018</u> |
|--|---------------------|-------------------|
| Financial assets: | | |
| Cash | \$ 2,676,766 | 1,486,517 |
| Restricted cash | 4,360,627 | 5,046,879 |
| Accounts receivable, net | 1,727,053 | 1,487,847 |
| Investments at fair value | <u>2,414,766</u> | <u>2,015,533</u> |
| Financial assets available at year-end | <u>11,179,212</u> | <u>10,036,776</u> |
| Less those unavailable for general expenditures within one year due to: | | |
| Restricted by donor with purpose restriction | 7,584,898 | 8,471,102 |
| Restriction by donor in perpetuity | <u>10,000</u> | <u>10,000</u> |
| Total limitations on available resources | <u>7,594,898</u> | <u>8,481,102</u> |
| Financial assets available to meet cash needs for general expenditures within one year | \$ <u>3,584,314</u> | <u>1,555,674</u> |

12. NEW ACCOUNTING PRONOUNCEMENTS:

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers*. The standard's core principle is that an organization will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the organization expects to be entitled in exchange for those goods or services. This standard also includes expanded disclosure requirements that result in an entity providing users of financial statements with comprehensive information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity's contracts with customers. This standard will be effective for CSC's year ending December 31, 2020.

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. The standard requires all leases with lease terms over 12 months to be capitalized as a right-of-use asset and lease liability on the statement of financial position at the date of the lease commencement. Leases will be classified as either financing or operating. This distinction will be relevant for the pattern of expense recognition in the consolidated statement of activities. This standard will be effective for CSC's year ending December 31, 2022.

CSC is currently in the process of evaluating the impact of adoption of these ASUs on the consolidated financial statements.

13. SUBSEQUENT EVENTS:

The COVID-19 outbreak in the United States has caused business disruption through closings of CSC's offices, postponement of CSC's annual spring gala and instability of significant funding sources. The effects of the pandemic have also led to significant declines in stock market indices. As a result of these declines, the value of CSC's investments declined from \$2,414,766 as of December 31, 2019, to

\$2,281,486 as of May 29, 2020, the most recent statement available. The extent of the impact of COVID-19 on CSC's operational and financial performance will depend on certain developments, including the duration and spread of the outbreak. Therefore, the impact on CSC's operations cannot be reasonably estimated and the extent to which COVID-19 may impact CSC's financial condition or results of operations is uncertain at this time.

Additionally, on April 27, 2020, CSC entered into a loan of \$793,600 under the Small Business Administration's Paycheck Protection Plan (PPP). The loan bears interest at 1% and is due in April 2022. The PPP program allows for a portion of the loan (up to the full amount) to be forgiven based on qualifying expenses. It is unknown at this time how much of the loan will be forgiven.

Cancer Support Community and Subsidiary
Consolidating Statement of Financial Position
December 31, 2019

| | <u>Cancer Support Community</u> | <u>Patient Planning Services, Inc.</u> | <u>Eliminations</u> | <u>Consolidated</u> |
|---|---|--|---------------------|---------------------|
| Assets | | | | |
| Cash and cash equivalents | \$ 2,518,708 | 158,058 | - | 2,676,766 |
| Restricted cash | 4,360,627 | - | - | 4,360,627 |
| Accounts receivable, net | 1,669,427 | 67,217 | (9,591) | 1,727,053 |
| Loan receivable - intercompany | 291,965 | - | (291,965) | - |
| Prepaid expenses | 190,272 | - | - | 190,272 |
| Investments | 2,469,776 | - | (55,010) | 2,414,766 |
| Property and equipment, net | 939,347 | 15,175 | - | 954,522 |
| Deposits | 106,183 | - | - | 106,183 |
| Total assets | <u>\$ 12,546,305</u> | <u>240,450</u> | <u>(356,566)</u> | <u>12,430,189</u> |
| Liabilities, Net Assets and Member's Equity | | | | |
| Liabilities: | | | | |
| Accounts payable | \$ 348,946 | 24,762 | (9,591) | 364,117 |
| Accrued expenses | 114,273 | 1,583 | - | 115,856 |
| Deferred revenue | - | 201,963 | - | 201,963 |
| Loan payable - intercompany | - | 291,965 | (291,965) | - |
| Other liabilities | 392,044 | - | - | 392,044 |
| Total liabilities | <u>855,263</u> | <u>520,273</u> | <u>(301,556)</u> | <u>1,073,980</u> |
| Net assets and stockholders' equity: | | | | |
| Without donor restrictions: | | | | |
| Controlling interest | 4,096,144 | - | (298,052) | 3,798,092 |
| Noncontrolling interest in PPS | - | - | (36,781) | (36,781) |
| Total without donor restrictions | <u>4,096,144</u> | <u>-</u> | <u>(334,833)</u> | <u>3,761,311</u> |
| With donor restrictions | 7,594,898 | - | - | 7,594,898 |
| Total net assets | <u>11,691,042</u> | <u>-</u> | <u>(334,833)</u> | <u>11,356,209</u> |
| Common stock | - | 10 | (10) | - |
| Preferred stock | - | 100,000 | (100,000) | - |
| Additional paid-in capital | - | 55,000 | (55,000) | - |
| Accumulated deficit | - | (434,833) | 434,833 | - |
| Total stockholders' equity | <u>-</u> | <u>(279,823)</u> | <u>279,823</u> | <u>-</u> |
| Total liabilities, net assets and stockholders' equity | <u>\$ 12,546,305</u> | <u>240,450</u> | <u>(356,566)</u> | <u>12,430,189</u> |

See accompanying independent auditors' report.

Cancer Support Community and Subsidiary
Consolidating Statement of Activities
Year Ended December 31, 2019

| | Without Donor Restrictions | With Donor Restrictions | PPS | Eliminations | Total |
|--|-------------------------------|----------------------------|------------------|------------------|-------------------|
| Revenues and other support: | | | | | |
| Contributions: | | | | | |
| Development income | \$ 1,013,080 | - | - | - | 1,013,080 |
| Program | 158,420 | 1,212,793 | - | - | 1,371,213 |
| Research and training | 1,047,274 | 810,564 | - | - | 1,857,838 |
| Events and special initiatives | 386,273 | 896,660 | - | - | 1,282,933 |
| Digital services and web | 386,688 | 173,680 | - | - | 560,368 |
| Education/Outreach | 1,011 | 2,215,000 | - | - | 2,216,011 |
| Policy/Advocacy | 1,171,500 | 1,065,740 | - | - | 2,237,240 |
| Special purpose funds | 75,019 | - | - | - | 75,019 |
| In-kind revenue | 9,443 | - | - | - | 9,443 |
| Affiliate activities | 520,310 | - | - | - | 520,310 |
| PPS sales, net of direct costs of \$52,477 | - | - | 390,829 | (170,298) | 220,531 |
| Miscellaneous income | 30,808 | - | - | - | 30,808 |
| Net investment return | 438,809 | - | - | - | 438,809 |
| Net assets released from restrictions | <u>7,260,641</u> | <u>(7,260,641)</u> | - | - | - |
| Total revenues and support | <u>12,499,276</u> | <u>(886,204)</u> | <u>390,829</u> | <u>(170,298)</u> | <u>11,833,603</u> |
| | | | | | |
| Expenses: | | | | | |
| Program services | 8,903,260 | - | - | (170,298) | 8,732,962 |
| Management and general | 729,633 | - | - | - | 729,633 |
| Fundraising | 838,796 | - | - | - | 838,796 |
| Operating expenses: PPS | - | - | <u>554,294</u> | - | <u>554,294</u> |
| Total expenses | <u>10,471,689</u> | <u>-</u> | <u>554,294</u> | <u>(170,298)</u> | <u>10,855,685</u> |
| | | | | | |
| Change in net assets | 2,027,587 | (886,204) | (163,465) | - | 977,918 |
| | | | | | |
| Net assets at beginning of year | <u>2,013,547</u> | <u>8,481,102</u> | <u>(116,358)</u> | - | <u>10,378,291</u> |
| | | | | | |
| Net assets (deficit) at end of year | \$ <u>4,041,134</u> | <u>7,594,898</u> | <u>(279,823)</u> | - | <u>11,356,209</u> |

See accompanying independent auditors' report.

